Last reviewed · How we verify
NCT03958812
Diagnostic Power Comparison Between VOCs and CTCs
trial testing Circulating tumor cells, Volatile organic compounds in Circulating Tumor Cell in 200 participants. Status unknown.
1 June 2020
Quick facts
| Lead sponsor | Anhui Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 15 June 2019 |
| Primary completion | 1 June 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- Circulating tumor cells, Volatile organic compounds
Conditions studied
- Circulating Tumor Cell — all drugs for Circulating Tumor Cell →
- Volatile Organic Chemicals — all drugs for Volatile Organic Chemicals →
- Breast Cancer — all drugs for Breast Cancer →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Anhui Medical University
Who can join
Adults 18 to 75, any sex, with Circulating Tumor Cell or Volatile Organic Chemicals. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early diagnosis of malignant tumors is pivotal for improving their prognoses. Circulating tumor cells (CTC) in peripheral blood and Volatile organic compounds (VOCs) in exhaled breath are newly developed diagnosis method. Due to the low percentage of CTCs in peripheral blood of cancer patients and the surface structure of lymphocytes (especially megakaryocytes) is often confused with tumor cells, CTC has a high false positive and negative rate. In recent years, the detection of volatile organic compounds (VOCs) in exhaled breath as a simple and noninvasive method has shown broad application prospects in the diagnosis of various diseases. A series of studies of VOCs diagnosing solid tumors the investigators had conducted in the past decade show that VOCs can not only distinguish different types of tumors, but also can make a distinction between different stages. This study was to compare CTC and VOCs with clinical samples. Predictive models will be built employing discriminant factor analysis (DFA) pattern recognition method. Sensitivity and specificity will be determined using leave-one-out cross-validation or an independent blind test set.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
Ma S, Wang X, Lin PP, Lei L. · · 2025 · cited 1× · PMID 40437761 · DOI 10.1002/cam4.70902
Verify or expand the search:
- PubMed search for NCT03958812
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Circulating Tumor Cell
Currently open trials in the same condition.
- NCT06755762 — Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer · recruiting
- NCT06391892 — Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery · Phase 3 · recruiting
- NCT05560776 — Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC · NA · active not recruiting
- NCT05815082 — ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer · Phase 3 · recruiting
- NCT05797077 — Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA · Phase 3 · recruiting
Other Anhui Medical University trials
Trials by the same sponsor.
- NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
- NCT07112612 — Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · not yet recruiting
- NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
- NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
- NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03958812 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
- Last refreshed: 3 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03958812.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing